Compare BMRA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRA | LGVN |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 21.4M |
| IPO Year | 1995 | 2021 |
| Metric | BMRA | LGVN |
|---|---|---|
| Price | $2.13 | $7.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 183.6K | ★ 426.9K |
| Earning Date | 04-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.81 | ★ 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,453,000.00 | $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.45 | $0.48 |
| 52 Week High | $3.21 | $7.30 |
| Indicator | BMRA | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 68.32 | 85.61 |
| Support Level | $2.05 | $0.61 |
| Resistance Level | $2.26 | $7.30 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | 0.04 | 0.26 |
| Stochastic Oscillator | 81.38 | 89.49 |
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.